Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Conditions:   Metastatic Anaplastic/Undifferentiated Thyroid Cancer;   Locally Advanced Anaplastic/Undifferentiated Thyroid CancerIntervention:   Drug: CeritinibSponsors:   University of Texas Southwestern Medical Center;   NovartisNot yet recruiting - verified November 2014

Source: ClinicalTrials.gov - October 6, 2014 Category: Research Source Type: clinical trials